Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 14;4:12. doi: 10.1186/s40364-016-0067-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Addition of plerixafor to rituximab treatment significantly increased the fraction of apoptotic cells. The anti-CD20 antibody rituximab (10 μg/mL) and/or the CXCR4 antagonist plerixafor (500 μM) were administered to the diffuse large B-cell lymphoma (DLBCL) cell lines RIVA (a) and FARAGE (b). The cells were subjected to flow cytometry-based analysis 48 h later, using a combination of 7-AAD and PE-conjugated Annexin V. One representative experiment per cell line is shown, with numbers indicating the percentage of cells in each quadrant. (c) The fractions of early apoptotic and late apoptotic/dead cells are summarized as mean of two independent experiments ± SEM, with each experiment containing technical triplicates. Statistical significance between groups was determined using a two-level linear mixed effects model. *p < 0.05; **p < 0.01; ***p < 0.001; RTX, rituximab; PLX, plerixafor; Q1, dead cells (AnnexinV⁻/7-AAD⁺); Q2, late apoptotic/dead cells (AnnexinV⁺/7-AAD⁺); Q3, early apoptotic cells (AnnexinV⁺/7-AAD⁻); Q4, living cells (AnnexinV⁻/7-AAD⁻)